Fontán-Vela, MarioKissling, EstherNicolay, NathalieBraeye, ToonVan Evercooren, IzaakHolm Hansen, ChristianEmborg, Hanne-DortheFabiani, MassimoMateo-Urdiales, AlbertoAlKerwi, Ala'aSchmitz, SusanneCastilla, JesúsMartínez-Baz, Ivánde Gier, BrechjeHahné, SusanMeijerink, HintaStarrfelt, JosteinNunes, BaltazarCaetano, ConstantinoDerrough, TarikNardone, AnthonyMonge Corella, SusanaVEBIS-Lot4 working group2024-03-182024-03-182024-01Euro Surveill. 2024 Jan;29(1):2300670.http://hdl.handle.net/20.500.12105/18983To monitor relative vaccine effectiveness (rVE) against COVID-19-related hospitalisation of the first, second and third COVID-19 booster (vs complete primary vaccination), we performed monthly Cox regression models using retrospective cohorts constructed from electronic health registries in eight European countries, October 2021-July 2023. Within 12 weeks of administration, each booster showed high rVE (≥ 70% for second and third boosters). However, as of July 2023, most of the relative benefit has waned, particularly in persons ≥ 80-years-old, while some protection remained in 65-79-year-olds.engVoRhttp://creativecommons.org/licenses/by/4.0/COVID-19SARS-CoV-2Cohort designElectronic health recordsHospitalisationMulti-country studyVaccine effectivenessCOVID-19HumansAtribución 4.0 Internacional38179626291230067010.2807/1560-7917.ES.2024.29.1.23006701560-7917Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletinopen access